Recent advances in the pharmacological management of pain.

abstract：:ZD1839 ('Iressa') is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor which blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and other host-dependent processes promoting cancer growth. In preclinical studies, ZD1839 produced reversib...

journal_title：Drugs

authors： Baselga J,Averbuch SD

更新日期：2000-01-01 00:00:00

abstract：:Methotrexate has been approved for the treatment of refractory rheumatoid arthritis by several regulatory agencies, including the Food and Drug Administration. The tendency is now to prescribe it at earlier stages of the disease. Methotrexate is a well known antifolate. Its exact mechanism of action in rheumatoid arth...

journal_title：Drugs

authors： Bannwarth B,Labat L,Moride Y,Schaeverbeke T

更新日期：1994-01-01 00:00:00

abstract：:Chronic pancreatitis is a clinical entity that results from the progressive inflammation and irreversible fibrosis of the pancreas resulting from the cumulative injury sustained by the pancreas over time. It is an illness with variable presentations that can severely impact quality of life, while its long-term complic...

journal_title：Drugs

authors： Kichler A,Jang S

更新日期：2020-08-01 00:00:00

abstract：:The efficacy of an antiretroviral (ARV) treatment regimen depends on the activity of the regimen's individual ARV drugs and the number of HIV-1 mutations required for the development of resistance to each ARV - the genetic barrier to resistance. ARV resistance impairs the response to therapy in patients with transmitt...

journal_title：Drugs

authors： Tang MW,Shafer RW

更新日期：2012-06-18 00:00:00

abstract：:Nausea and vomiting continue to be critical problems in cancer chemotherapy, although considerable progress has been made toward understanding the neuropharmacological mechanisms of vomiting and how chemotherapeutic agents and antiemetics affect these mechanisms. The principles of behavioural psychology have also been...

journal_title：Drugs

authors： Triozzi PL,Laszlo J

更新日期：1987-07-01 00:00:00

abstract：:An increase in serum digoxin concentration occurs in 90% of patients given quinidine. On average, the serum digoxin doubles during treatment with therapeutic doses of quinidine. Almost every patient treated with quinidine will have a decrease in the renal clearance of digoxin and many will have a decrease in the volum...

journal_title：Drugs

authors： Bigger JT Jr,Leahey EB Jr

更新日期：1982-09-01 00:00:00

abstract：:Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the last two decades, with modest improvements in quality of life and overall survival. A plateau has been reached with traditional chemotherapy, and efforts are now being directed at developing molecularly targeted agents. To date, thre...

journal_title：Drugs

authors： Triano LR,Deshpande H,Gettinger SN

更新日期：2010-01-01 00:00:00

abstract：:Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...

journal_title：Drugs

authors： Scott LJ

更新日期：2020-03-01 00:00:00

abstract：:Iloprost is an analogue of epoprostenol (prostacyclin; PGI2; a potent but short-lived prostanoid mainly produced in the vascular endothelium) and mimics the pharmacodynamic properties of this compound, namely: inhibition of platelet aggregation, vasodilatation and, as yet ill-defined, cytoprotection. Improved metaboli...

journal_title：Drugs

authors： Grant SM,Goa KL

更新日期：1992-06-01 00:00:00

abstract：:Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic pleuromutilin with a chemical structure that contains a tricyclic core of five-, six-, and eight-membered rings and a 2-(4-amino-2-hydroxycyclohexy...

journal_title：Drugs

authors： Zhanel GG,Deng C,Zelenitsky S,Lawrence CK,Adam HJ,Golden A,Berry L,Schweizer F,Zhanel MA,Irfan N,Bay D,Lagacé-Wiens P,Walkty A,Mandell L,Lynch JP 3rd,Karlowsky JA

更新日期：2020-11-28 00:00:00

abstract：:It is important to distinguish between therapy used to reduce acute inflammation in gout and therapy used to manage hyperuricaemia in patients with chronic gouty arthritis. This article discusses treatments for acute gout, emphasizing the use of corticotrophin (adrenocorticotropic hormone; ACTH) and the evidence on wh...

journal_title：Drugs

authors： Schlesinger N

更新日期：2008-01-01 00:00:00

abstract：:All 27 EU member states and another seven countries participate in the European Surveillance of Antimicrobial Consumption (ESAC) project. ESAC carried out three hospital point-prevalence surveys on antimicrobial use. Point-prevalence surveys linked antimicrobial use to indication and also assessed dosing using a stand...

journal_title：Drugs

authors： Zarb P,Goossens H

更新日期：2011-04-16 00:00:00

abstract：:The rationale for the use of nifedipine in patients with acute myocardial infarction (MI) is based on the various cardiovascular actions of the compound: reduction of myocardial oxygen consumption by attenuation of cardiac and vascular smooth muscle tension; augmentation of oxygen and substrate supply after increased ...

journal_title：Drugs

authors： Rafflenbeul W,Ebner F

更新日期：1991-01-01 00:00:00

abstract：:Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t½ of approximately 24 h and unique pharmacok...

journal_title：Drugs

authors： Ceriello A,De Nigris V,Iijima H,Matsui T,Gouda M

更新日期：2019-05-01 00:00:00

abstract：:A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic ...

journal_title：Drugs

authors： Keating GM

更新日期：2016-04-01 00:00:00

abstract：:Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab is approved in several countries, including in the USA and...

journal_title：Drugs

authors： Blair HA

更新日期：2019-10-01 00:00:00

abstract：:Influenza vaccines form the mainstay of public health and personal protection against infection with seasonal influenza viruses. These vaccines are designed to protect people against infection with the currently circulating influenza viruses. Since the late 1970s, this has required the use of a trivalent vaccine consi...

journal_title：Drugs

authors： Barr IG,Jelley LL

更新日期：2012-12-03 00:00:00

abstract：:There have been a number of controlled trials of antacids in the treatment of patients with peptic ulcer disease. As a general rule the size of studies has been small and there have been difficulties ensuring adequate binding, because of the formulation and taste of the antacids. Despite these difficulties, antacids a...

journal_title：Drugs

authors： Walt RP,Langman MJ

更新日期：1991-08-01 00:00:00

abstract：:Cardiovascular diseases are the leading cause of mortality in industrialized countries. Treatment with statins is effective in primary prevention in patients at high cardiovascular risk. Statins are inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase and are classed as lipid-lowering drugs. In 2010, ato...

journal_title：Drugs

authors： Lecarpentier E,Morel O,Fournier T,Elefant E,Chavatte-Palmer P,Tsatsaris V

更新日期：2012-04-16 00:00:00

abstract：:Pomalidomide (Imnovid®; Pomalyst®), an analogue of thalidomide, is an immunomodulatory agent, with several mechanisms of action (both direct and indirect) thought to be involved in its anti-myeloma activity. Oral pomalidomide is available in several countries for use in combination with low-dose dexamethasone in adult...

journal_title：Drugs

authors： Hoy SM

更新日期：2017-11-01 00:00:00

abstract：:67 samples of 15 different tissues were obtained from 26 patients who were given an intravenous bolus dose of temocillin approximately 3 to 4 hours prior to surgery. 50 tissue samples were obtained from 19 patients who received 1g temocillin and 17 tissue samples were obtained from 7 patients who received 2g temocilli...

journal_title：Drugs

authors： Gould JG,Meikle G,Cooper DL,Horton R

更新日期：1985-01-01 00:00:00

abstract：:Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. In primary prevention, CARDS (Collaborative Atorvastatin Diabetes Study) showed that atorvastatin 10 mg/day (vs p...

journal_title：Drugs

authors： Arca M

更新日期：2007-01-01 00:00:00

abstract：:The naturally occurring catecholamines, noradrenaline, adrenaline and dopamine, have been found in a wide range of animal and vegetable tissues, but are particularly associated with nervous tissue in animals. Of the many processes affecting the response to stimulation of catecholamine containing nerves, the synthesis ...

journal_title：Drugs

authors： Laverty R

更新日期：1978-11-01 00:00:00

abstract：:The potential beneficial effects of antihypertensive drugs on cardiovascular morbidity and mortality may be compromised by their adverse effects on serum lipid levels. In our study we compared verapamil and captopril and evaluated their effects on blood pressure and on serum lipid and lipoprotein levels, with particul...

journal_title：Drugs

authors： Catalano M,Cislaghi C,Carzaniga G,Aronica A,Seregni R,Libretti A

更新日期：1992-01-01 00:00:00

abstract：:Desloratadine is the orally active major metabolite of the nonsedating H1-antihistamine loratadine. The drug had no adverse cardiovascular effects in various animal models or when administered at 9 times the recommended adult dosage for 10 days in volunteers. Therapeutic dosages had no effects on wakefulness or psycho...

journal_title：Drugs

authors： McClellan K,Jarvis B

更新日期：2001-01-01 00:00:00

abstract：:Intravenous minocycline (Minocin®) is approved in the USA for use in patients with infections due to susceptible strains of Gram-positive and Gram-negative pathogens, including infections due to Acinetobacter spp. Minocycline is a synthetic tetracycline derivative that was originally introduced in the 1960s. A new int...

journal_title：Drugs

authors： Greig SL,Scott LJ

更新日期：2016-10-01 00:00:00

abstract：:Childhood obesity has become the most common paediatric disorder in the developed world. Treatment of obesity in children may include lifestyle interventions, pharmacotherapy and weight-loss supplements. The outcome of lifestyle interventions, which classically include dietary modifications, increased activity and beh...

journal_title：Drugs

authors： Rogovik AL,Chanoine JP,Goldman RD

更新日期：2010-02-12 00:00:00

abstract：:Atenolol and nifedipine have been shown to be effective single agents in angina pectoris, but reports suggest that additional benefits may be conferred by combining the 2 drugs. Therefore, to establish that the combination regimen was at least as effective as either atenolol or nifedipine alone, a multicentre study wa...

journal_title：Drugs

authors： Sandberg M,Foale RA

更新日期：1988-01-01 00:00:00

abstract：:Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-positive and -negative bacterial strains expressing certain common tetracycline-specific acquired...

journal_title：Drugs

authors： Scott LJ

更新日期：2019-02-01 00:00:00

abstract：:Acute myocardial infarction (AMI) recognises no boundaries, and the patient's greatest need occurs at the interface between primary care and hospital system. Ideally, the general practitioner, if summoned, should be able to provide resuscitation, analgesia with opiates, and thrombolytic therapy. Thrombolytics should c...

journal_title：Drugs

authors： Rawles J

更新日期：1995-10-01 00:00:00